Related Experiment Video
Updated: May 5, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Triple antithrombotic therapy in cardiac patients: more questions than answers
Martin Moser1, Christoph B Olivier, Christoph Bode
1Heart Center, Cardiology and Angiology I, Freiburg University, Hugstetter Strasse 55, Freiburg 79106, Germany.
Insights
Managing cardiac patients on combined antithrombotic therapy, including anticoagulants and anti-platelet drugs, poses bleeding risks. This review explores strategies to minimize bleeding while preventing ischemic events in conditions like atrial fibrillation and acute coronary syndrome.
Area of Science:
- Cardiology
- Pharmacology
- Thrombosis Research
Background:
- Many cardiac patients need combined antithrombotic therapy (anticoagulant and anti-platelet inhibition).
- Common indications include atrial fibrillation (AF) with drug-eluting stents or acute coronary syndrome (ACS).
- Standard dosing regimens increase bleeding rates.
Purpose of the Study:
- To review current literature on combined antithrombotic therapy.
- To discuss approaches for reducing bleeding risk.
- To maintain efficacy in preventing ischemic events.
Main Methods:
- Literature review of existing studies on antithrombotic therapy.
- Analysis of bleeding and ischemic event rates.
- Evaluation of risk-reduction strategies.
Main Results:
- Combined antithrombotic therapy is frequently indicated but associated with high bleeding rates.
- Optimal drug combinations and dosages remain undetermined.
- Strategies to mitigate bleeding risk are under investigation.
Conclusions:
- Balancing bleeding and ischemic risks is crucial in combined antithrombotic therapy.
- Further research is needed to establish optimal treatment protocols.
- Minimizing bleeding complications without compromising efficacy is a key therapeutic goal.
Abstract:
Many cardiac patients require combined antithrombotic therapy consisting of an anticoagulant and inhibition of platelet function. The most frequent indications are atrial fibrillation (AF) in combination with drug-eluting stent implantation and/or the presence of an acute coronary syndrome (ACS). Currently, the optimal combination of anticoagulants and anti-platelet therapy is unknown, but it is well established that the combination of regular doses and regimens as prescribed in AF or after ACS results in increased bleeding rates. In this review, we discuss the current literature and describe approaches to reduce the risk of bleeding hoping not to increase the rate of ischaemic events.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Atherosclerosis III: Management
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Peripheral Artery Disease III: Interprofessional Care

